Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy, Dry Eye, and Ocular Surface Diseases.
Vitam Horm. 2016.
PMID: 27450739
Review.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2012 | 1 |
| 2015 | 4 |
| 2016 | 2 |
| 2018 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 0 |
Search Results
13 results
Results by year
Citations
2
articles
found by citation matching
Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.
Clin Ophthalmol. 2015.
PMID: 26056426
Free PMC article.
Search results
Page 1
Thymosin beta 4 and the eye: the journey from bench to bedside.
Expert Opin Biol Ther. 2018 Jul;18(sup1):99-104. doi: 10.1080/14712598.2018.1486818.
Expert Opin Biol Ther. 2018.
PMID: 30063853
Review.
Thymosin beta 4 (Tbeta4) has important applications in ocular repair and Phase 3 clinical trials using Tbeta4 to treat dry eye and neurotrophic keratopathy are currently ongoing. ...Expert opinion: The electrifying possibility of Tbeta4 as a rev …
Thymosin beta 4 (Tbeta4) has important applications in ocular repair and Phase 3 clinical trials using Tbeta4 to treat …
Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy, Dry Eye, and Ocular Surface Diseases.
Vitam Horm. 2016;102:277-306. doi: 10.1016/bs.vh.2016.04.012. Epub 2016 Jul 5.
Vitam Horm. 2016.
PMID: 27450739
Review.
Chronic ocular surface diseases such as dry eye, blepharitis, and neurotrophic keratopathies represent a significant and a growing therapeutic challenge. ...A focus on treatments that reduce the inflammatory responses while accelerating corneal epithelial growth wou …
Chronic ocular surface diseases such as dry eye, blepharitis, and neurotrophic keratopathies represent a significant and a gro …
Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model.
Clin Ophthalmol. 2015 May 20;9:877-84. doi: 10.2147/OPTH.S80954. eCollection 2015.
Clin Ophthalmol. 2015.
PMID: 26056426
Free PMC article.
BACKGROUND: The purpose of this study was to evaluate the safety and efficacy of thymosin beta 4 ophthalmic solution (RGN-259; Tbeta4) in subjects with moderate to severe dry eye using the CAE model. ...CONCLUSION: This study confirms the effica …
BACKGROUND: The purpose of this study was to evaluate the safety and efficacy of thymosin beta 4 ophthalmic solution (R …
Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis.
Int Immunopharmacol. 2023 May;118:109953. doi: 10.1016/j.intimp.2023.109953. Epub 2023 Apr 3.
Int Immunopharmacol. 2023.
PMID: 37018981
Free PMC article.
To this end, treatments are needed that both regulate the inflammatory response and promote corneal wound healing to resolve visual disturbances and improve quality of life. Thymosin beta 4 is a small, naturally occurring 43-amino-acid protein that promotes w …
To this end, treatments are needed that both regulate the inflammatory response and promote corneal wound healing to resolve visual disturba …
Thymosin beta4: a potential novel dry eye therapy.
Ann N Y Acad Sci. 2012 Oct;1270:45-50. doi: 10.1111/j.1749-6632.2012.06682.x.
Ann N Y Acad Sci. 2012.
PMID: 23050816
Review.
The purpose of this manuscript is to review the clinical entity of dry eye syndrome (DES) and to provide a scientific basis and rationale for the usage of thymosin beta 4 (Tbeta4) as a novel therapy for DES. ...Based on previous studies, there i …
The purpose of this manuscript is to review the clinical entity of dry eye syndrome (DES) and to provide a scientific basis an …
Primary Mechanisms of Thymosin beta4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries.
Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5110-7. doi: 10.1167/iovs.15-16890.
Invest Ophthalmol Vis Sci. 2015.
PMID: 26241398
Review.
Dry eye disorders are becoming more common due to many causes, including an aging population, increased pollution, and postrefractive surgery. ...We will also speculate on additional mechanisms that might promote eye repair based on data from other tissue inj …
Dry eye disorders are becoming more common due to many causes, including an aging population, increased pollution, and postref …
Thymosin beta(4) and beta(10) in Sjogren's syndrome: saliva proteomics and minor salivary glands expression.
Arthritis Res Ther. 2016 Oct 6;18(1):229. doi: 10.1186/s13075-016-1134-7.
Arthritis Res Ther. 2016.
PMID: 27716395
Free PMC article.
Recombinant Human Thymosin beta4 (rhTbeta4) Modulates the Anti-Inflammatory Responses to Alleviate Benzalkonium Chloride (BAC)-Induced Dry Eye Disease.
Int J Mol Sci. 2022 May 13;23(10):5458. doi: 10.3390/ijms23105458.
Int J Mol Sci. 2022.
PMID: 35628276
Free PMC article.
Dry eye disease (DED) is a multifactorial ocular disorder that interferes with daily living and reduces quality of life. ...Mechanically, the rhTbeta4 groups showed significantly reduced inflammatory cytokine levels and CD4(+) T cells in conjunctiva by blocking NF-k …
Dry eye disease (DED) is a multifactorial ocular disorder that interferes with daily living and reduces quality of life. ...Me …
Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.
Cornea. 2015 May;34(5):491-6. doi: 10.1097/ICO.0000000000000379.
Cornea. 2015.
PMID: 25826322
Clinical Trial.
PURPOSE: Standard therapies for severe dry eye are limited and fail to resolve the problem. The purpose of this study was to evaluate the safety and efficacy of Thymosin beta4 eye drops (RGN-259) as a novel therapy for severe dry eye disease (in …
PURPOSE: Standard therapies for severe dry eye are limited and fail to resolve the problem. The purpose of this study was to e …
Thymosin beta4 significantly reduces the signs of dryness in a murine controlled adverse environment model of experimental dry eye.
Expert Opin Biol Ther. 2015;15 Suppl 1:S155-61. doi: 10.1517/14712598.2015.1019858. Epub 2015 Jun 22.
Expert Opin Biol Ther. 2015.
PMID: 26096547
OBJECTIVE: Dry eye syndrome is a common condition that affects up to 20% of the population aged 45 and older. ...CONCLUSIONS: Tbeta4 has the potential to be an important new effective therapeutic for dry eye....
OBJECTIVE: Dry eye syndrome is a common condition that affects up to 20% of the population aged 45 and older. ...CONCLUSIONS: …
Cite